← All trials
NCT02950051
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2016
- Primary completion
- Jan 1, 2023
- Completion date
- Jan 1, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 920
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- German CLL Study GroupLead sponsor
- University of CologneOverall official - principal investigator
- Swiss Group for Clinical Cancer ResearchCollaborator
- HOVON - Dutch Haemato-Oncology AssociationCollaborator
- Nordic CLL Study Group (NCLLSG)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.